ALK and breast cancer: Notably, the most represented or highest-valued kinase inhibitors in terms of mean difference sensitivity among ERα-positive and ERα-negative BC cell lines or p-value were those targeting ALK or AURKA and AURKB (Fig. 1d and Supplementary Table S1).